More About Us!

>> We recently updated our brochure about Highland Ophthalmology Vision Care Facility in New Windsor. Click here to view and print a copy!


ARTICLES

>> Article Written by Dr. Mary Davidian "Amniotic Membrane For Ocular Inflammation" Ophthalmology Management, June 1, 2013


NEWS


>>
Highland Ophthalmology Associates Offering New FDA-Approved Avedro Corneal Collagen Cross-Linking Procedure to Keratoconus Patients

>>
Highland Ophthalmology Establishes a Dry Eye Center of Excellence in the Hudson Valley of New York

>> Medical Eye Specialist Dr. Julia Mathews Joins New Windsor, New York Practice Highland Ophthalmology

>>
Highland Ophthalmology Introduces LipiFlow to Address Dry Eye Syndrome Caused by MGD

>>
Medical Eye Specialist Dr. Michael Stagner Joins New Windsor, New York Practice Highland Ophthalmology

>> Dr. Mary Davidian to Appear on American Health Front Program on NBC

>> Need for Eye Surgery Lessened by New Corneal Wound and Healing Treament

>> Highland Ophthalmology Opens New State-of-the-Art Vision Center

>> Highland Ophthalmology Celebrates Grand Opening of New Vision Center in New Windsor

>> Newburgh Ophthalmologists Offer Free Glaucoma Screenings Jan. 24

>> High-Tech Eye Care Right Here at Home

>> Eye Doctors Urge Exams During Glaucoma Awareness Month

>> Glaucoma Specialist Joins New Windsor, NY Ophthalmology Practice

>> New Windsor, NY Eye Surgeon Offers Alcon’s AcrySof® ReSTOR® Intraocular Lens for Cataract Correction

>> Alcon Launches AcrySof® ReSTOR® Apodized Diffractive IOL; Revolutionary Apodized Diffractive Technology Provides Highest Level of Freedom from Glasses

>> CMS Ruling Provides Medicare Patients Access to Alcon’s AcrySof® ReSTOR® IOL

 


 

Alcon AcrySof® IQ ReSTOR® IOLs FAQs

For Cataract Eye Surgery

 

With more than 50 million implants in cataract surgeries worldwide, the AcrySof® family of lenses are the most frequently used intraocular lenses (IOLs) in the world, largely because physicians appreciate the long-term clinical results and unmatched stability.

The first multifocal IOL of its kind, the AcrySof® IQ ReSTOR® IOL draws upon decades of expertise and technology for an intraocular lens that truly helps cataract patients see it all—near, far, and everything in between—without the need for reading glasses or bifocals after surgery.

In a clinical trial, after having the AcrySof® IQ ReSTOR® IOL implanted in both eyes, at 6 months post-op, 78 percent of patients reported not needing glasses.

Nearly 94 percent of patients (implanted with the +3.0 D IOL) indicated that they would have the lenses implanted again, according to a patient satisfaction survey.

Here’s what makes AcrySof® IQ ReSTOR® IOLs so unique:

  • The majority of modern IOLs are made from either silicone or a hard plastic called polymethylmethacrylate (PMMA), but AcrySof® IQ ReSTOR® IOL uses a soft, foldable acrylic, which makes implantation easier for the surgeon and more comfortable for the patient. A smaller incision also removes the need for stitches, providing faster recovery times and clearer, more youthful vision.
  • With AcrySof® IQ ReSTOR® IOL, patients with both cataracts and presbyopia can have both conditions corrected at the same time, eliminating the need for spectacles after surgery in most patients.

Click on the play button to
see how the AcrySof
® IQ ReSTOR® IOL works.

 

OptiLASIK® Laser Vision Correction

Myopia:

  • Approval of the premarket approval application is for the WaveLight®ALLEGRETTO WAVE®/ ALLEGRETTO WAVE® Eye-Q Excimer Laser System to perform LASIK treatments in patients 18 years of age or older for the reduction or elimination of myopic refractive errors up to -12.0 diopters (D) of sphere with and without astigmatic refractive errors up to -6.0 D; and in patients with documented evidence of a stable manifest refraction defined as less than or equal to 0.50 D of preoperative spherical equivalent shift over one year prior to surgery.
  • LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), and other refractive surgeries.
  • Approval of the application is based on clinical trials in the United States with 901 eyes treated, of which 813 of 866 eligible eyes were followed for 12 months. Accountability at 3 months was 93.8%, at 6 months was 91.9%, and at 12 months was 93.9%.
  • The studies found that of the 844 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at the 3-month stability time point, 98.0% were corrected to 20/40 or better, and 84.4% were corrected to 20/20 or better without spectacles or contact lenses.
  • The clinical trials showed that the following subjective patient adverse events were reported as "moderate to severe" at a level at least 1% higher than baseline of the subjects at 3 months posttreatment: visual fluctuations (12.8% at baseline versus 28.6% at 3 months).
  • Long-term risks of LASIK for myopia with and without astigmatism beyond 12 months have not been studied.
  • Note that the complete name for this ophthalmic laser is "WaveLight®ALLEGRETTO WAVE® / ALLEGRETTO WAVE® Eye-Q Excimer Laser System for laser assisted in-situ keratomileusis (LASIK) treatments of myopic refractive errors up to -12.0 diopters (D) of sphere with and without astigmatic refractive errors up to -6.0 D at the spectacle plane."

Hyperopia:

  • Approval of the premarket approval application is for the WaveLight®ALLEGRETTO WAVE®/ ALLEGRETTO WAVE® Eye-Q Excimer Laser System to perform LASIK treatments in patients 18 years of age or older for the reduction or elimination of hyperopic refractive errors up to +6.0 diopters (D) of sphere with and without astigmatic refractive errors up to 5.0 D at the spectacle plane, with a maximum manifest refraction spherical equivalent (MRSE) of +6.0 D; and in patients with documented evidence of a stable manifest refraction defined as less than or equal to 0.50 D of preoperative spherical equivalent shift over one year prior to surgery, exclusive of changes due to unmasking latent hyperopia.
  • LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), and other refractive surgeries.
  • Approval of the application is based on clinical trials in the United States with 290 eyes treated, of which 100 of 290 eligible eyes were followed for 12 months. Accountability at 3 months was 95.2%, at 6 months was 93.9%, and at 12 months was 69.9%.
  • The studies found that of the 212 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at the 6-month stability time point, 95.3% were corrected to 20/40 or better, and 67.5% were corrected to 20/20 or better without spectacles or contact lenses.
  • The study showed that the following subjective patient adverse events were reported as "much worse" by at least 1% of the subjects (in order of increasing frequency) at 6 months post final treatment: glare from bright lights (3.0%); night driving glare (4.2%) light sensitivity (4.9%); visual fluctuations (6.1%); and halos (6.4%).
  • Long term risks of LASIK for hyperopia with and without astigmatism beyond 12 months have not been studied.
  • Note that the complete name for this ophthalmic laser is "WaveLight®ALLEGRETTO WAVE®/ ALLEGRETTO WAVE® Eye—Q Excimer Laser System for laser assisted in-situ keratomileusis (LASIK) treatments of hyperopic refractive errors up to +6.0 diopters (D) of sphere with and without astigmatic refractive errors up to 5.0 D with a maximum manifest refraction spherical equivalent (MRSE) of +6.0 D."

Mixed Astigmatism:

  • Approval of the premarket approval application is for the WaveLight®ALLEGRETTO WAVE®/ ALLEGRETTO WAVE® Eye-Q Excimer Laser System to perform LASIK treatments in patients 21 years of age or older for the reduction or elimination of naturally occurring mixed astigmatism of up to 6.00 D at the spectacle plane; and in patients with documentation of a stable manifest refraction defined as less than or equal to 0.50 D of preoperative spherical equivalent shift over one year prior to surgery.
  • LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), and other refractive surgeries.
  • Approval of the application is based on clinical trials in the United States with 162 eyes treated, of which 111 were eligible to be followed at 6 months. Accountability at 1 month was 99.4%, at 3 months was 96.0%, and at 6 months was 100.0%.
  • The studies found that of the 142 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at the 3-month stability time point, 95.8% achieved acuity of 20/40 or better, and 67.6% achieved acuity of 20/20 or better without spectacles or contact lenses.
  • The clinical trials showed that the following subjective patient adverse events were reported as "moderate to severe" at a level at least 1% higher than baseline of the subjects at 3 months post-treatment: sensitivity to light (43.3% at baseline versus 52.9% at 3 months); visual fluctuations (32.1% at baseline versus 43.0% at 3 months); and halos (37.0% at baseline versus 42.3% at 3 months).
  • Long term risks of LASIK for mixed astigmatism beyond 6 months have not been studied.
  • The safety and effectiveness of LASIK surgery has ONLY been established with an optical zone of 6.0 - 7.0 mm and an ablation zone of 9.0 mm.
  • Note that the complete name for this ophthalmic laser is "WaveLight®ALLEGRETTO WAVE®/ ALLEGRETTO WAVE® Eye-Q Excimer Laser System for laser assisted in-situ keratomileusis (LASIK) treatments of naturally occurring mixed astigmatism of up to 6.00 D at the spectacle plane."

Wavefront-Guided Treatment of Myopia:

  • Approval of the premarket approval application is for the WaveLight®ALLEGRETTO WAVE® / ALLEGRETTO WAVE® Eye-Q Excimer Laser System used in conjunction with the WaveLight® Analyzer device. The device uses a 6.5 mm optical zone, a 9.0 mm ablation/treatment zone, and is indicated for wavefront-guided (WFG) laser assisted in-situ keratomileusis (LASIK):
    1) for the reduction or elimination of up to -7.00 diopters (D) of spherical equivalent myopia or myopia with astigmatism, with up to -7.00 D of spherical component and up to 3.00 D of astigmatic component at the spectacle plane;
    2) in patients who are 18 years of age or older; and
    3) in patients with documentation of a stable manifest refraction defined as ≤0.50 D of preoperative spherical equivalent shift over one year prior to surgery.
  • LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), traditional LASIK and other refractive surgeries.
  • Approval of the application is based on a randomized clinical trial in the United States with 374 eyes treated; 188 with wavefront-guided LASIK (Study Cohort) and 186 with Wavefront Optimized® LASIK (Control Cohort). 178 of the Study Cohort and 180 of the Control Cohort were eligible to be followed at 6 months. In the Study Cohort, accountability at 1 month was 96.8%, at 3 months was 96.8%, and at 6 months was 93.3%. In the Control Cohort, accountability at 1 month was 94.6%, at 3 months was 94.6%, and at 6 months was 92.2%.
  • The studies found that of the 180 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at the 6-month stability time point in the Study Cohort, 99.4% were corrected to 20/40 or better, and 93.4% were corrected to 20/20 or better without spectacles or contact lenses. In the Control Cohort, of the 176 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at the 6-month stability time point, 99.4% were corrected to 20/40 or better, and 92.8% were corrected to 20/20 or better without spectacles or contact lenses.
  • The clinical trials showed that the following subjective patient adverse events were reported as "moderate to severe" at a level at least 1% higher than baseline of the subjects at 3 months post-treatment in the Study Cohort, light sensitivity (37.2% at baseline versus 47.8% at 3 months) and visual fluctuations (13.8% at baseline versus 20.0% at 3 months). In the Control Cohort, halos (36.6% at baseline versus 45.4% at 3 months) and visual fluctuations (18.3% at baseline versus 21.9% at 3 months).
  • Long term risks of wavefront-guided LASIK for myopia with and without astigmatism beyond 6 months have not been studied.
  • Note that the complete name for this ophthalmic laser is "WaveLight®ALLEGRETTO WAVE® / ALLEGRETTO WAVE® Eye-Q Excimer Laser System used in conjunction with the WaveLight® Analyzer device. The device uses a 6.5 mm optical zone, a 9.0 mm ablation/treatment zone, and is indicated for wavefront-guided (WFG) laser-assisted in-situ keratomileusis (LASIK): 1) for the reduction or elimination of up to -7.00 diopters (D) of spherical equivalent myopia or myopia with astigmatism, with up to -7.00 D of spherical component and up to 3.00 D of astigmatic component at the spectacle plane; 2) in patients who are 18 years of age or older; and 3) in patients with documentation of a stable manifest refraction defined as ≤0.50 D of preoperative spherical equivalent shift over one year prior to surgery."

 


Our office is within an easy commute from the following areas in the Hudson Valley and Orange County and Dutchess County: New Windsor, Cornwall, Fishkill, Middletown, Florida, Warwick, Monroe, Harriman, Fort Montgomery, Highland Falls, Marlboro, Walden, Wallkill, Pine Bush, Vails Gate, Goshen, Salisbury Mills, Washingtonville, Campbell Hall, Montgomery, West Point, Modena, New Paltz, Highland, Beacon, Castle Point, Wappingers Falls, Poughkeepsie, NY.

With this, Highland Ophthalmology has become New Windsor's leading specialty eye care center. Call (845) 562-0138 today for your first consultation.





Highland Ophthalmology Associates on LinkedIn

     | 

 


To expedite your visit to Highland Ophthalmology please download and complete a New Patient Information Form prior to your first visit and present it to the receptionist when checking in:

Contact Us

Call us at (845) 562-0138 or fill out and submit this form to learn more about Highland Ophthalmology.

Please Note: Do not use this form for emergency purposes.

Name:*
Email:*
Phone:*
Comments:
* Required Fields

I agree to the Terms of Use
and Privacy Policy.


By checking the box, you are indicating that you have read, understand and consent to Highland Ophthalmology Associates Terms of Use and Privacy Policy.

 



AcrySof® IQ Toric IOLs

 


AcrySof® IQ ReSTOR® IOLs

 



PROKERA®

 


 


 

 

TearLab® Osmolarity System

 



Copyright © 2016
Highland Ophthalmology Associates, LLC.
All rights reserved.

140 Executive Drive
New Windsor, NY 12553

Telephone (845) 562-0138
Fax (845) 562-0147

To see a map of our location and get directions, click here.

   
About HOA Procedures

Dr. Mary Davidian
Dr. Thien Huynh
Dr. Julia Mathew
Dr. Michael Stagner
Dr. Sharon Bean Powell
Dr. Miriam Rolf

Cataract Treatment
Cornea Transplants
Glaucoma Treatment
Dry Eye Treatment